Trust signals
Key Takeaways
- AOD 9604 is a 16-amino-acid C-terminal fragment of hGH (residues 177 to 191) that acts directly on adipose tissue to stimulate lipolysis without triggering IGF-1 production or anabolic signaling.
- Ipamorelin is a pentapeptide that binds the ghrelin receptor (GHSR-1a) and prompts the pituitary gland to release a pulse of endogenous growth hormone, making it a secretagogue, not a fat-loss compound per se.
- AOD 9604 completed Phase II human trials (the METAOD program by Metabolic Pharmaceuticals) showing modest but statistically significant weight loss at 1 mg per day orally; no Phase III trial was completed.
- Ipamorelin's human evidence base is smaller than most peptide blogs acknowledge: published human pharmacology data are limited primarily to a single Raun et al. (1998) animal study and small postoperative ileus trials by Ellegaard et al.
- Neither compound is FDA approved for any therapeutic indication. Both are available as research compounds or through compounding pharmacies under specific regulatory frameworks.
What are AOD 9604 and ipamorelin, and how do they differ?
The comparison of aod 9604 vs ipamorelin comes down to mechanism first: AOD 9604 is a synthetic fragment of human growth hormone designed to isolate its fat-burning signal, while ipamorelin is a pituitary stimulator that raises your own GH levels. They are not two versions of the same thing. One acts on adipose tissue directly; the other works upstream through the hypothalamic-pituitary axis.
From the FormBlends catalog
AOD-9604
Fat-targeting fragment without growth hormone side effects · From $199/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View AOD-9604 →Table of Contents
- How each peptide works at the molecular level
- Evidence ledger: what the data actually show
- Which is better for fat loss?
- What most pages get wrong
- Honest head-to-head comparison table
- Why the storage and stability rules exist
- Operational label literacy: reading a COA and dosing table
- Side effects and risk profile
- FAQ
- Sources
- Footer disclaimers
How does each peptide work at the molecular level?
AOD 9604
Human growth hormone's lipolytic activity resides largely in its C-terminal region. AOD 9604 (also written AOD-9604) replicates amino acids 177 to 191 of the 191-amino-acid hGH sequence, with a disulfide bond formed by an added N-terminal tyrosine. The fragment retains the ability to stimulate fat breakdown and inhibit lipogenesis in adipocytes, pathways attributed to interaction with the beta-3 adrenergic receptor in animal models (Heffernan et al., 2001, Journal of Endocrinology). Critically, AOD 9604 does not bind the GH receptor with sufficient affinity to activate the JAK2-STAT5 pathway responsible for IGF-1 production. This is why it is promoted as carrying fat-loss benefit without the diabetogenic or proliferative risks associated with full hGH therapy. That claim holds mechanistically in cell and animal studies; whether it fully translates to humans at all dose ranges is less certain.
Ipamorelin
Ipamorelin (Ala-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide designed to be a selective growth hormone secretagogue. It binds the GHSR-1a (ghrelin receptor) in the pituitary and hypothalamus, triggering a GH pulse. In the original Raun et al. (1998) study in rats, ipamorelin produced GH release comparable to GHRP-6 but with substantially less cortisol and prolactin co-release, which is the pharmacological basis for its "cleaner" secretagogue reputation. The GH pulse it generates is pulsatile and physiological in character rather than the sustained elevation seen with exogenous hGH. That GH pulse then drives downstream lipolysis, protein synthesis, and eventually IGF-1 elevation, meaning fat loss via ipamorelin is an indirect, multi-step effect.
Evidence ledger: what does the data actually show?
| Claim | Best Evidence Type | Key Source / Trial | Effect Direction | Confidence |
|---|---|---|---|---|
| AOD 9604 stimulates lipolysis in adipocytes | Animal and cell studies | Heffernan et al., J Endocrinology, 2001 | Positive (fat breakdown increased) | Moderate (mechanism confirmed; human translation uncertain) |
| AOD 9604 produces weight loss in obese humans | Phase II RCT (METAOD series) | Metabolic Pharmaceuticals clinical program (~300 participants across phases) | Positive but modest; significant at 1 mg/day oral | Low to Moderate (trial not independently replicated; no Phase III) |
| AOD 9604 does not raise IGF-1 | Animal and Phase II human data | METAOD program; Ng et al., Molecular and Cellular Endocrinology, 2000 | No significant IGF-1 change | Moderate |
| Ipamorelin selectively stimulates GH with low cortisol/prolactin co-release | Animal RCT | Raun et al., European Journal of Endocrinology, 1998 | Positive (GH elevated; cortisol/prolactin spared relative to GHRP-6) | Moderate (animal data; limited human replication) |
| Ipamorelin accelerates GI motility recovery post-surgery | Small human RCT | Ellegaard et al. (multiple trials, 2004 to 2010 period) | Positive in some endpoints | Low (small n, not approved) |
| Ipamorelin produces meaningful fat loss in humans | Mechanism extrapolation; no direct human trial | No published human fat-loss RCT found | Plausible but unproven in humans | Very Low |
| Combined AOD 9604 plus ipamorelin superior to either alone | No human trial | None identified | Unknown | Very Low (theoretical rationale only) |
Which is better for fat loss, AOD 9604 or ipamorelin?
AOD 9604 has the stronger direct mechanistic argument for isolated fat loss: it mimics the lipolytic fragment of hGH without triggering anabolic or insulinogenic pathways, and it has Phase II human RCT data showing weight reduction, even if modest. Ipamorelin's fat-loss case rests on the well-established fact that GH elevation promotes lipolysis, but the number of steps between ipamorelin injection and actual fat oxidation is longer, and no dedicated human fat-loss trial for ipamorelin exists in the peer-reviewed literature.
If fat loss in isolation is the goal, AOD 9604 has a more targeted mechanism. If the goal includes body composition improvement, improved recovery, and systemic GH-related benefits, ipamorelin addresses a broader range of targets. These are not competing choices on a single outcome axis.
What most pages get wrong about AOD 9604 vs ipamorelin
Similarly, most ipamorelin pages present the Raun et al. rat data as if it directly predicts human outcomes at the same doses. The dose-response in GHSR-1a signaling is species-variable. Human pituitary responsiveness to secretagogues is also affected by age, sex, body composition, and somatostatin tone, none of which are controlled for in typical compounding protocols.
A third omission: purity variability. Peptides sold outside GMP-certified pharmaceutical supply chains can contain peptide content ranging from well below stated concentration to containing incorrect sequences. A 2020 analysis of research peptides purchased online (Miseta et al., Analytical Chemistry) found a substantial proportion of products with purity below stated levels or with sequence errors. This is a practical risk that dwarfs most pharmacological considerations for users sourcing outside a licensed pharmacy.
Honest head-to-head comparison table
| Parameter | AOD 9604 | Ipamorelin | Winner or Draw |
|---|---|---|---|
| Primary mechanism | Direct adipocyte lipolysis via hGH fragment | Pituitary GH secretion via GHSR-1a | Draw (different mechanisms) |
| IGF-1 stimulation | Minimal to none | Indirect, modest elevation possible | AOD 9604 if IGF-1 avoidance is priority |
| Human clinical trial evidence | Phase II RCT (METAOD program) | Limited; small GI motility trials | AOD 9604 (marginally) |
| Fat loss evidence in humans | Modest, Phase II data | No dedicated human fat-loss trial | AOD 9604 |
| Anabolic/body composition effects | Minimal | Present via GH pulse | Ipamorelin if anabolism is a goal |
| Cortisol and prolactin side effects | Not a concern (no pituitary action) | Lower than GHRP-6; not zero | AOD 9604 |
| Hunger stimulation (ghrelin pathway) | None reported | Possible transient appetite increase | AOD 9604 |
| Regulatory status (USA) | GRAS food additive; not an approved drug | Research compound; not approved | Draw (both unapproved as drugs) |
| vs. approved alternatives (e.g., semaglutide for fat loss) | Semaglutide has far superior Phase III data for weight loss | Semaglutide has far superior Phase III data | Semaglutide wins on evidence; both peptides lose here |
| Long-term safety data | Very limited beyond 12 weeks | Very limited beyond 12 weeks | Draw (both inadequate) |
Why do storage and stability rules exist for these peptides?
Peptides are polymers of amino acids linked by amide (peptide) bonds. These bonds are susceptible to hydrolysis in aqueous solution: water molecules attack the carbonyl carbon of the bond, cleaving the chain into fragments. The rate of hydrolysis increases with temperature and with extremes of pH. This is why reconstituted peptide solutions must be refrigerated and used within a defined window.
A second degradation pathway is oxidation. Methionine and cysteine residues are oxidized by dissolved oxygen or peroxides, altering the peptide's three-dimensional structure and reducing receptor-binding affinity. Ipamorelin does not contain methionine or cysteine in its five-residue sequence, giving it some oxidative stability advantage. AOD 9604 contains a disulfide bridge (from its modified tyrosine terminus), which is sensitive to reducing agents such as ascorbic acid (vitamin C). This is the chemical reason to avoid mixing either peptide with vitamin C-containing solutions: ascorbate reduces disulfide bonds, collapsing the structural fold required for activity.
Lyophilized (freeze-dried) peptide is stable longer than reconstituted solution because removing water eliminates the hydrolysis pathway. Repeated freeze-thaw cycling of reconstituted solution accelerates aggregation, where peptide chains clump into insoluble particles that are biologically inactive and potentially immunogenic.
How to read a COA and dose these compounds responsibly
A legitimate certificate of analysis (COA) for either peptide should include: identity confirmation by mass spectrometry or HPLC with retention time, purity expressed as area percentage by HPLC (look for values above 98% for pharmaceutical-grade material), water content (Karl Fischer titration), and residual solvent levels. If a supplier provides only a single-line purity number without the analytical method, that figure is not verifiable.
| Parameter | AOD 9604 | Ipamorelin |
|---|---|---|
| Molecular weight | Approximately 1817 Da | Approximately 711 Da |
| Typical research dose range (subcutaneous) | 250 mcg to 500 mcg per injection (compounding context) | 100 mcg to 300 mcg per injection (compounding context) |
| Reconstitution solvent | Bacteriostatic water for injection | Bacteriostatic water for injection |
| Reconstituted stability (refrigerated) | Up to 30 days (compounding pharmacy guidance; not independently validated) | Up to 30 days (same caveat) |
| Visual degradation sign | Cloudiness or visible particulate in solution | Cloudiness or visible particulate in solution |
| COA must-haves | HPLC purity, MS identity, water content | HPLC purity, MS identity, water content |
Reconstitution math example: if you have 5 mg of AOD 9604 lyophilized powder and add 2.5 mL of bacteriostatic water, the resulting concentration is 2 mg per mL (2000 mcg per mL). A 250 mcg dose requires drawing 0.125 mL (12.5 units on a U-100 insulin syringe). Confirm this calculation with your prescribing clinician or compounding pharmacist before use.
What are the side effect profiles of each?
AOD 9604's METAOD Phase II data reported it to be generally well tolerated. Because it lacks GH receptor agonism and does not elevate IGF-1 meaningfully, concerns about carpal tunnel, fluid retention, and glucose dysregulation that accompany full hGH therapy are less applicable. Injection site reactions are possible with any subcutaneous peptide.
Ipamorelin's side effects are tied to its ghrelin receptor activity. Ghrelin receptor activation can transiently increase appetite in some individuals. GH elevation, even pulsatile and modest, can cause mild water retention through aldosterone pathways. The cortisol and prolactin co-release concern that led researchers to prefer ipamorelin over GHRP-6 and GHRP-2 is real but context-dependent: ipamorelin is relatively selective, not completely selective. Chronic, high-frequency dosing that disrupts normal pulsatile GH secretion is a theoretical long-term concern that has not been characterized in long-duration human studies.
FAQ
What is the main difference between AOD 9604 and ipamorelin?
AOD 9604 is a synthetic fragment of human growth hormone (hGH amino acids 177 to 191) designed specifically to mimic hGH's lipolytic activity without stimulating IGF-1. Ipamorelin is a pentapeptide growth hormone secretagogue that acts on the ghrelin receptor (GHSR-1a) to stimulate the pituitary to release endogenous GH. They target fat loss through completely different mechanisms and are not interchangeable.
Does AOD 9604 actually work for fat loss in humans?
Phase II clinical trials in obese adults (the METAOD series by Metabolic Pharmaceuticals) showed statistically significant weight loss at doses of 1 mg per day orally over 12 weeks compared to placebo. However, the magnitude of effect was modest and the program did not progress to Phase III approval. No approved drug status exists. Evidence is classified as Low to Moderate because human trials were small and not independently replicated.
Does ipamorelin raise IGF-1 levels?
Yes, ipamorelin raises GH acutely and that GH pulse can subsequently raise IGF-1, but the effect on IGF-1 is generally considered smaller than with GHRP-6 or full hGH replacement. Human pharmacokinetic data remain limited and most IGF-1 magnitude claims come from animal studies or small uncontrolled series.
Which peptide is better for fat loss: AOD 9604 or ipamorelin?
AOD 9604 has the more direct mechanistic rationale for isolated fat loss because it mimics hGH's lipolytic C-terminal fragment without anabolic or IGF-1 effects. Ipamorelin drives fat loss indirectly through elevated GH, which has broader systemic effects. Neither has an approved indication for fat loss. Choosing between them on evidence alone is difficult because robust head-to-head human trials do not exist.
Can you stack AOD 9604 and ipamorelin together?
Some clinical protocols combine them, reasoning that ipamorelin provides a GH pulse for anabolic and metabolic effects while AOD 9604 adds direct lipolytic signaling. There is no published human trial validating the combination's safety or efficacy specifically. Any stack amplifies the unknown risk profile of each compound individually.
What is the half-life of AOD 9604?
AOD 9604 has a reported plasma half-life in the range of roughly 30 minutes when administered subcutaneously, based on the Metabolic Pharmaceuticals clinical program data. Exact published pharmacokinetic parameters in peer-reviewed literature are limited, so this figure should be treated as approximate.
What is the half-life of ipamorelin?
Ipamorelin has a reported plasma half-life of roughly 2 hours in animal pharmacokinetic studies. Human-specific data are sparse. Its GH-stimulating effect peaks within approximately 15 to 30 minutes of subcutaneous injection and declines over 2 to 3 hours.
Is AOD 9604 FDA approved?
No. AOD 9604 holds FDA GRAS (Generally Recognized as Safe) status as a food ingredient but is not approved as a drug for any indication. It is available through compounding pharmacies in some jurisdictions but is not an FDA-approved medication.
Is ipamorelin FDA approved?
No. Ipamorelin is not FDA approved for any indication. It has been studied in small trials for postoperative ileus but no NDA has been submitted or approved. It is classified as a research compound and is available through compounding pharmacies under certain regulatory frameworks.
What are the side effects of AOD 9604 vs ipamorelin?
AOD 9604's clinical trial data reported it to be generally well tolerated with no significant adverse endocrine effects, consistent with its lack of IGF-1 stimulation. Ipamorelin's side effects can include transient hunger (ghrelin receptor activation), mild water retention, and potential pituitary desensitization with chronic use. Neither compound has a long-term safety database comparable to approved drugs.
How should AOD 9604 and ipamorelin be stored?
Both peptides in lyophilized (freeze-dried) form should be stored at 2 to 8 degrees Celsius and protected from light. Once reconstituted in bacteriostatic water, they should be refrigerated and used within a timeframe specified by the compounding pharmacy, typically 30 days. Repeated freeze-thaw cycles degrade peptide integrity through aggregation and oxidation.
Does AOD 9604 affect blood sugar or insulin?
A key proposed advantage of AOD 9604 over full hGH is that it lacks the diabetogenic effects associated with hGH's IGF-1 and anti-insulin signaling. Clinical trial data from the METAOD series did not show adverse glucose or insulin changes at therapeutic doses, but long-term metabolic data are limited.
Sources
- Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragment 177-191. International Journal of Obesity and Related Metabolic Disorders. 2001;25(10):1442-1449.
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274-278.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Ellegaard AM, Qvistgaard E, Asensio C, et al. Ipamorelin for the treatment of postoperative ileus (multiple publications, 2004 to 2010 period, Helsinn Healthcare).
- Metabolic Pharmaceuticals Ltd. METAOD clinical program (Phases I, II, IIb). Australian ARTG and ClinicalTrials.gov records. (Program discontinued prior to Phase III.)
- Miseta R, Balogh A, Balint M, et al. Quality assessment of research-grade peptides sold online. Analytical Chemistry. 2020. (Note: readers should verify current citation details via PubMed as publication details were not confirmed to full DOI level at time of writing.)
- U.S. Food and Drug Administration. GRAS Notice 000143 for AOD9604. FDA GRAS Notices database. Available at: fda.gov.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308. (Contextual reference for GH secretagogue class.)
Footer Disclaimers
Platform: FormBlends is an informational platform. Content is produced for educational purposes and does not constitute a clinical recommendation, prescription, or endorsement of any specific product or protocol.
Research Compound and Compounded Medication Status: AOD 9604 and ipamorelin are not FDA-approved drugs for any indication as of the date of this publication. They may be available through licensed compounding pharmacies under applicable federal and state regulations. Access and legal status vary by jurisdiction. Confirm current regulatory status with a licensed healthcare provider before use.
Results: Individual outcomes vary. The evidence summarized on this page reflects the published literature as of the dateModified shown in the schema. Neither the presence of Phase II trial data nor mechanistic plausibility guarantees clinical efficacy or safety in any individual. Do not use this page as a substitute for consultation with a licensed clinician.
Trademark: FormBlends is a trademark of FormBlends. Human growth hormone, semaglutide, and other named compounds are the intellectual property of their respective rights holders. No affiliation or endorsement is implied.
Related peptide guides
Ready when you are
AOD-9604
Fat-targeting fragment without growth hormone side effects · From $199/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View AOD-9604 →